Mixed Results for Gilead Sciences' COVID-19 Treatment
Late on Friday afternoon before Memorial Day weekend, a leading medical journal published results from a government-sponsored clinical trial with the experimental coronavirus treatment, remdesivir. The blinded, randomized study showed clear evidence that treatment with Gilead Sciences' (NASDAQ: GILD) experimental antiviral drug helped patients recover faster, but investigators from the National Institute of Allery and Infectious Disease (NIAID) couldn't find clear evidence of a survival benefit.
Remdesivir's main goal in the NIAID study was shortened time to recovery and Gilead's antiviral candidate clearly hit the mark. A majority of patients treated with remdesivir recovered in 11 days or less compared to a median recovery time of 15 days for patients given a placebo.
Image source: Getty Images.
Source Fool.com
